<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TOPIRAMATE</span><br/>(to-pir'a-mate)<br/><span class="topboxtradename">Topamax<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 100 mg, 200 mg tablets; 15 mg, 25 mg, 50 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Sulfamate-substituted monosaccharide with a broad spectrum of anticonvulsant activity. Its precise mechanism of action is
         unknown. Exhibits sodium channel-blocking action, as well as enhancing the ability of GABA to induce a flux of chloride ions
         into the neurons, thus potentiating the activity of this inhibitory neurotransmitter (GABA).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by a decrease in seizure activity. Effectively controls partial onset seizures in adults and children by inhibiting
         GABA.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy for partial-onset seizures in adults and children age 216 y; generalized tonic-clonic seizures; migraine
         prophylaxis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Cluster headache, bulimia nervosa, neuropathic pain, infantile spasms, weight loss.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to topiramate; epilepsy, pregnancy (category C). Effect on labor and delivery is unknown.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate and severe renal impairment, hepatic impairment; lactation. While topiramate has been studied in patients 217
         y of age, safety and effectiveness in younger children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Partial-Onset Seizures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with 25 mg b.i.d., increase by 50 mg/wk to  efficacy <span class="rdroute">PO Maintenance Dose</span> 200400 mg/d divided b.i.d. (max: 1600 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>216 y,</i> Initiate with 13 mg/kg h.s. <small>x</small> 1 wk, then increase by 13 mg/kg/d in 2 divided doses q12wk
               to a target range of 59 mg/kg/d<br/><br/><span class="indicationtitle">Generalized Tonic-Clonic</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i></i> Initiate with 13 mg/kg h.s.; titrate to 6 mg/kg/d by the end of 8 wk<br/><br/><span class="indicationtitle">Migraine Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with 25 mg b.i.d., increase by 25 mg/wk to 200 mg/d or max tolerated dose<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Make dosage increments of 50 mg at weekly intervals to the recommended dose, usually 400 mg/d.</li>
<li>Do not break tablets unless absolutely necessary because of bitter taste.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container. Protect from light and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> <span class="speceff-common">Fatigue, speech problems,</span> weight loss; decreased sweating and hyperthermia in children; metabolic acidosis. <span class="typehead">CNS:</span> <span class="speceff-common">Somnolence, dizziness, ataxia, psychomotor slowing, confusion, nystagmus, paresthesia, memory difficulty, difficulty concentrating,
         nervousness,</span> depression, anxiety, tremor. <span class="typehead">GI:</span> Anorexia. <span class="typehead">Special Senses:</span> Angle closure glaucoma (rare). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased CNS depression with <b>alcohol</b> and other <span class="classification">cns depressants</span>; may increase <b>phenytoin</b> concentrations; may decrease <span class="classification">oral contraceptive</span>, <b>valproate</b> concentrations; may increase risk of kidney stone formation with other <span class="classification">carbonic anhydrase inhibitors</span>. <b>Carbamazepine,</b> <b>phenytoin,</b> <b>valproate</b> may decrease topiramate concentrations. <span class="typehead">Herbal:</span> <b>Ginkgo</b> may decrease anticonvulsant effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; 80% bioavailability. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> 1317% protein bound. <span class="typehead">Metabolism:</span> Minimally metabolized in the liver. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 21 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor mental status and report significant cognitive impairment.</li>
<li>Lab tests: Periodically monitor CBC with Hgb and Hct.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not stop drug abruptly; discontinue gradually to minimize seizures.</li>
<li>To minimize risk of kidney stones, drink at least 68 full glasses of water each day.</li>
<li>Exercise caution with potentially hazardous activities. Sedation is common, especially with concurrent use of alcohol or other
            CNS depressants.
         </li>
<li>Use or add barrier contraceptive if using hormonal contraceptives.</li>
<li>Be aware that psychomotor slowing and speech/language problems may develop while on topiramate therapy.</li>
<li>Report adverse effects that interfere with activities of daily living.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>